메뉴 건너뛰기




Volumn 135, Issue 3, 2014, Pages 595-605

Primary debulking surgery for advanced ovarian cancer: Are you a believer or a dissenter?

Author keywords

Advanced ovarian cancer; Neoadjuvant chemotherapy; Primary debulking surgery

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN;

EID: 84920740775     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2014.10.007     Document Type: Review
Times cited : (41)

References (117)
  • 1
    • 63149087256 scopus 로고    scopus 로고
    • Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: Results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)
    • Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 2009; 10:327-40.
    • (2009) Lancet Oncol , vol.10 , pp. 327-340
    • Menon, U.1    Gentry-Maharaj, A.2    Hallett, R.3    Ryan, A.4    Burnell, M.5    Sharma, A.6
  • 3
    • 79958036419 scopus 로고    scopus 로고
    • Effect of screening on ovarian cancer mortality: The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial
    • Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 2011;305:2295-303.
    • (2011) JAMA , vol.305 , pp. 2295-2303
    • Buys, S.S.1    Partridge, E.2    Black, A.3    Johnson, C.C.4    Lamerato, L.5    Isaacs, C.6
  • 4
    • 84867136524 scopus 로고    scopus 로고
    • Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement
    • Moyer VA. Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med 2012;157:900-4.
    • (2012) Ann Intern Med , vol.157 , pp. 900-904
    • Moyer, V.A.1
  • 5
    • 77956285631 scopus 로고    scopus 로고
    • Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer
    • Vergote I, Trope CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010;363:943-53.
    • (2010) N Engl J Med , vol.363 , pp. 943-953
    • Vergote, I.1    Trope, C.G.2    Amant, F.3
  • 6
    • 32144437596 scopus 로고    scopus 로고
    • Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients
    • Earle CC, Schrag D, Neville BA, Yabroff KR, Topor M, Fahey A, et al. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst 2006;98:172-80.
    • (2006) J Natl Cancer Inst , vol.98 , pp. 172-180
    • Earle, C.C.1    Schrag, D.2    Neville, B.A.3    Yabroff, K.R.4    Topor, M.5    Fahey, A.6
  • 7
    • 31544431784 scopus 로고    scopus 로고
    • Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma
    • Engelen MJ, Kos HE,Willemse PH, et al. Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma. Cancer 2006;106: 589-98.
    • (2006) Cancer , vol.106 , pp. 589-598
    • Engelen, M.J.1    Kos, H.E.2    Willemse, P.H.3
  • 8
    • 0036141256 scopus 로고    scopus 로고
    • A population-based study of patterns of care for ovarian cancer: Who is seen by a gynecologic oncologist and who is not?
    • Carney ME, Lancaster JM, Ford C, et al. A population-based study of patterns of care for ovarian cancer: who is seen by a gynecologic oncologist and who is not? Gynecol Oncol 2002;84:36-42.
    • (2002) Gynecol Oncol , vol.84 , pp. 36-42
    • Carney, M.E.1    Lancaster, J.M.2    Ford, C.3
  • 10
    • 0016586897 scopus 로고
    • Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma
    • Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 1975;42:101-4.
    • (1975) Natl Cancer Inst Monogr , vol.42 , pp. 101-104
    • Griffiths, C.T.1
  • 11
    • 0018373579 scopus 로고
    • Role of cytoreductive surgical treatment in the management of advanced ovarian cancer
    • Griffiths CT, Parker LM, Fuller Jr AF. Role of cytoreductive surgical treatment in the management of advanced ovarian cancer. Cancer Treat Rep 1979;63:235-40.
    • (1979) Cancer Treat Rep , vol.63 , pp. 235-240
    • Griffiths, C.T.1    Parker, L.M.2    Fuller, A.F.3
  • 13
    • 0023941862 scopus 로고
    • The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma
    • Piver MS, Lele SB, Marchetti DL, et al. The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma. J Clin Oncol 1988;6:983-9.
    • (1988) J Clin Oncol , vol.6 , pp. 983-989
    • Piver, M.S.1    Lele, S.B.2    Marchetti, D.L.3
  • 14
    • 84905090642 scopus 로고    scopus 로고
    • Metastatic colorectal cancer: Survival comparison of hepatic resection versus cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
    • Blackham AU, Russell GB, Stewart JH, Votanopoulos K, Levine EA, Shen P. Metastatic colorectal cancer: survival comparison of hepatic resection versus cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2014;21: 2667-74.
    • (2014) Ann Surg Oncol , vol.21 , pp. 2667-2674
    • Blackham, A.U.1    Russell, G.B.2    Stewart, J.H.3    Votanopoulos, K.4    Levine, E.A.5    Shen, P.6
  • 15
    • 84908357109 scopus 로고    scopus 로고
    • Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
    • Heng DY, Wells JC, Rini BI, Beuselinck B, Lee JL, Knox JJ, et al. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol 2014;66:704-10.
    • (2014) Eur Urol , vol.66 , pp. 704-710
    • Heng, D.Y.1    Wells, J.C.2    Rini, B.I.3    Beuselinck, B.4    Lee, J.L.5    Knox, J.J.6
  • 16
    • 84905961448 scopus 로고    scopus 로고
    • Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: Results of the GYMSSA trial
    • Rudloff U, Langan RC, Mullinax JE, Beane JD, Steinberg SM, Beresnev T, et al. Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial. J Surg Oncol 2014;110:275-84.
    • (2014) J Surg Oncol , vol.110 , pp. 275-284
    • Rudloff, U.1    Langan, R.C.2    Mullinax, J.E.3    Beane, J.D.4    Steinberg, S.M.5    Beresnev, T.6
  • 17
    • 84862565067 scopus 로고    scopus 로고
    • Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal sarcomatosis
    • Salti GI, Ailabouni L, Undevia S. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal sarcomatosis. Ann Surg Oncol 2012;19:1410-5.
    • (2012) Ann Surg Oncol , vol.19 , pp. 1410-1415
    • Salti, G.I.1    Ailabouni, L.2    Undevia, S.3
  • 18
    • 0033812797 scopus 로고    scopus 로고
    • A critique of surgical cytoreduction in advanced ovarian cancer
    • Covens AL. A critique of surgical cytoreduction in advanced ovarian cancer. Gynecol Oncol 2000;78:269-74.
    • (2000) Gynecol Oncol , vol.78 , pp. 269-274
    • Covens, A.L.1
  • 19
    • 78650060554 scopus 로고    scopus 로고
    • Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppression
    • Napoletano C, Bellati F, Landi R, Pauselli S, Marchetti C, Visconti V, et al. Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppression. J Cell Mol Med 2010;14:2748-59.
    • (2010) J Cell Mol Med , vol.14 , pp. 2748-2759
    • Napoletano, C.1    Bellati, F.2    Landi, R.3    Pauselli, S.4    Marchetti, C.5    Visconti, V.6
  • 20
    • 79955002720 scopus 로고    scopus 로고
    • Evidence for cancer stem cells contributing to the pathogenesis of ovarian cancer
    • Curley MD, Garrett LA, Schorge JO, Foster R, Rueda BR. Evidence for cancer stem cells contributing to the pathogenesis of ovarian cancer. Front Biosci 2011;16: 368-92.
    • (2011) Front Biosci , vol.16 , pp. 368-392
    • Curley, M.D.1    Garrett, L.A.2    Schorge, J.O.3    Foster, R.4    Rueda, B.R.5
  • 21
    • 16844368698 scopus 로고    scopus 로고
    • Tumour stem cells and drug resistance
    • Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005;5:275-84.
    • (2005) Nat Rev Cancer , vol.5 , pp. 275-284
    • Dean, M.1    Fojo, T.2    Bates, S.3
  • 22
    • 0018569942 scopus 로고
    • A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate
    • Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979;63:1727-33.
    • (1979) Cancer Treat Rep , vol.63 , pp. 1727-1733
    • Goldie, J.H.1    Coldman, A.J.2
  • 23
    • 33751416878 scopus 로고    scopus 로고
    • The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer
    • Eisenhauer EL, Abu-Rustum NR, Sonoda Y, et al. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol 2006;103:1083-90.
    • (2006) Gynecol Oncol , vol.103 , pp. 1083-1090
    • Eisenhauer, E.L.1    Abu-Rustum, N.R.2    Sonoda, Y.3
  • 24
    • 0041622805 scopus 로고    scopus 로고
    • Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: A prospective study
    • Eisenkop SM, Spirtos NM, Friedman RL, et al. Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol Oncol 2003;90:390-6.
    • (2003) Gynecol Oncol , vol.90 , pp. 390-396
    • Eisenkop, S.M.1    Spirtos, N.M.2    Friedman, R.L.3
  • 25
    • 0026620239 scopus 로고
    • The in fluence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: A Gynecologic Oncology Group study
    • Hoskins WJ, Bundy BN, Thigpen JT, Omura GA. The in fluence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 1992;47: 159-66.
    • (1992) Gynecol Oncol , vol.47 , pp. 159-166
    • Hoskins, W.J.1    Bundy, B.N.2    Thigpen, J.T.3    Omura, G.A.4
  • 26
    • 0028237380 scopus 로고
    • The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patientswith suboptimal residual epithelial ovarian carcinoma
    • Hoskins WJ, McGuire WP, Brady MF, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patientswith suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994;170:974-9.
    • (1994) Am J Obstet Gynecol , vol.170 , pp. 974-979
    • Hoskins, W.J.1    McGuire, W.P.2    Brady, M.F.3
  • 28
    • 30044438368 scopus 로고    scopus 로고
    • Intraperitoneal cisplatin and paclitaxel in ovarian cancer
    • Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:34-43.
    • (2006) N Engl J Med , vol.354 , pp. 34-43
    • Armstrong, D.K.1    Bundy, B.2    Wenzel, L.3
  • 29
    • 36849043690 scopus 로고    scopus 로고
    • Prospective study of the correlation between postoperative computed tomography scan and primary surgeon assessment in patients with advanced ovarian, tubal, and peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease 1 cm or less
    • Chi DS, Ramirez PT, Teitcher JB, et al. Prospective study of the correlation between postoperative computed tomography scan and primary surgeon assessment in patients with advanced ovarian, tubal, and peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease 1 cm or less. J Clin Oncol 2007;25:4946-51.
    • (2007) J Clin Oncol , vol.25 , pp. 4946-4951
    • Chi, D.S.1    Ramirez, P.T.2    Teitcher, J.B.3
  • 30
    • 79956119117 scopus 로고    scopus 로고
    • The value of post-operative/preadjuvant chemotherapy computed tomography in the management of patients with ovarian cancer
    • Sala E, Mannelli L, Yamamoto K, Griffin M, Griffin N, Grant L, et al. The value of post-operative/preadjuvant chemotherapy computed tomography in the management of patients with ovarian cancer. Int J Gynecol Cancer 2011;21:296-301.
    • (2011) Int J Gynecol Cancer , vol.21 , pp. 296-301
    • Sala, E.1    Mannelli, L.2    Yamamoto, K.3    Griffin, M.4    Griffin, N.5    Grant, L.6
  • 31
    • 34548491626 scopus 로고    scopus 로고
    • Prognostic factors for stage III epithelial ovarian cancer: A Gynecologic Oncology Group study
    • Winter III WE, Maxwell GL, Tian C, et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2007;25:3621-7.
    • (2007) J Clin Oncol , vol.25 , pp. 3621-3627
    • Winter, W.E.1    Maxwell, G.L.2    Tian, C.3
  • 32
    • 84862777804 scopus 로고    scopus 로고
    • Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: Redefining 'optimal' residual disease
    • Chang SJ, Bristow RE. Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: redefining 'optimal' residual disease. Gynecol Oncol 2012; 125:483-92.
    • (2012) Gynecol Oncol , vol.125 , pp. 483-492
    • Chang, S.J.1    Bristow, R.E.2
  • 34
    • 84876463750 scopus 로고    scopus 로고
    • Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer
    • Chang SJ, Bristow RE, Ryu HS. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer. Ann Surg Oncol 2012;19:4059-67.
    • (2012) Ann Surg Oncol , vol.19 , pp. 4059-4067
    • Chang, S.J.1    Bristow, R.E.2    Ryu, H.S.3
  • 35
    • 33750145025 scopus 로고    scopus 로고
    • What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?
    • Chi DS, Eisenhauer EL, Lang J, et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol 2006;103:559-64.
    • (2006) Gynecol Oncol , vol.103 , pp. 559-564
    • Chi, D.S.1    Eisenhauer, E.L.2    Lang, J.3
  • 36
    • 62349140395 scopus 로고    scopus 로고
    • Quality improvement in the surgical approach to advanced ovarian cancer: The Mayo Clinic experience
    • Aletti GD, Dowdy SC, Gostout BS, et al. Quality improvement in the surgical approach to advanced ovarian cancer: the Mayo Clinic experience. J Am Coll Surg 2009;208:614-20.
    • (2009) J Am Coll Surg , vol.208 , pp. 614-620
    • Aletti, G.D.1    Dowdy, S.C.2    Gostout, B.S.3
  • 37
    • 67349224121 scopus 로고    scopus 로고
    • Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm
    • Chi DS, Eisenhauer EL, Zivanovic O, et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol 2009;114:26-31.
    • (2009) Gynecol Oncol , vol.114 , pp. 26-31
    • Chi, D.S.1    Eisenhauer, E.L.2    Zivanovic, O.3
  • 38
    • 79957478333 scopus 로고    scopus 로고
    • Impact of a structured qualitymanagement program on surgical outcome in primary advanced ovarian cancer
    • Harter P, Muallem ZM, Buhrmann C, Lorenz D, Kaub C, Hils R, et al. Impact of a structured qualitymanagement program on surgical outcome in primary advanced ovarian cancer. Gynecol Oncol 2011;121:615-9.
    • (2011) Gynecol Oncol , vol.121 , pp. 615-619
    • Harter, P.1    Muallem, Z.M.2    Buhrmann, C.3    Lorenz, D.4    Kaub, C.5    Hils, R.6
  • 39
    • 84882454584 scopus 로고    scopus 로고
    • Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: A meta-analysis
    • Chang SJ, Hodeib M, Chang J, Bristow RE. Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis. Gynecol Oncol 2013;130:493-8.
    • (2013) Gynecol Oncol , vol.130 , pp. 493-498
    • Chang, S.J.1    Hodeib, M.2    Chang, J.3    Bristow, R.E.4
  • 40
    • 84908319713 scopus 로고    scopus 로고
    • The impacts of neoadjuvant chemotherapy and of debulking surgery on survival from advanced ovarian cancer
    • Rosen B, Laframboise S, Ferguson S, Dodge J, Bernardini M, Murphy J, et al. The impacts of neoadjuvant chemotherapy and of debulking surgery on survival from advanced ovarian cancer. Gynecol Oncol 2014;134:462-7.
    • (2014) Gynecol Oncol , vol.134 , pp. 462-467
    • Rosen, B.1    Laframboise, S.2    Ferguson, S.3    Dodge, J.4    Bernardini, M.5    Murphy, J.6
  • 41
    • 84879097208 scopus 로고    scopus 로고
    • Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: A Gynecologic Oncology Group study
    • Landrum LM, Java J, Mathews CA, Lanneau Jr GS, Copeland LJ, Armstrong DK, et al. Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study. Gynecol Oncol 2013;130:12-8.
    • (2013) Gynecol Oncol , vol.130 , pp. 12-18
    • Landrum, L.M.1    Java, J.2    Mathews, C.A.3    Lanneau, G.S.4    Copeland, L.J.5    Armstrong, D.K.6
  • 43
    • 84862754523 scopus 로고    scopus 로고
    • Outcome of immediate re-operation or interval debulking after chemotherapy at a gynecologic oncology center after initially incomplete cytoreduction of advanced ovarian cancer
    • Grabowski JP, Harter P, Hils R, Lorenz D, Kaub C, Barinoff J, et al. Outcome of immediate re-operation or interval debulking after chemotherapy at a gynecologic oncology center after initially incomplete cytoreduction of advanced ovarian cancer. Gynecol Oncol 2012;126:54-7.
    • (2012) Gynecol Oncol , vol.126 , pp. 54-57
    • Grabowski, J.P.1    Harter, P.2    Hils, R.3    Lorenz, D.4    Kaub, C.5    Barinoff, J.6
  • 44
    • 34648840675 scopus 로고    scopus 로고
    • A new frontier for quality of care in gynecologic oncology surgery: Multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model
    • Aletti GD, Santillan A, Eisenhauer EL, Hu J, Aletti G, Podratz KC, et al. A new frontier for quality of care in gynecologic oncology surgery: multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model. Gynecol Oncol 2007;107:99-106.
    • (2007) Gynecol Oncol , vol.107 , pp. 99-106
    • Aletti, G.D.1    Santillan, A.2    Eisenhauer, E.L.3    Hu, J.4    Aletti, G.5    Podratz, K.C.6
  • 45
    • 84857498751 scopus 로고    scopus 로고
    • Surgical risk score predicts suboptimal debulking or a major perioperative complication in patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer
    • Stashwick C, Post MD, Arruda JS, Spillman MA, Behbakht K, Davidson SA, et al. Surgical risk score predicts suboptimal debulking or a major perioperative complication in patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. Int J Gynecol Cancer 2011;21:1422-7.
    • (2011) Int J Gynecol Cancer , vol.21 , pp. 1422-1427
    • Stashwick, C.1    Post, M.D.2    Arruda, J.S.3    Spillman, M.A.4    Behbakht, K.5    Davidson, S.A.6
  • 46
    • 84871929181 scopus 로고    scopus 로고
    • Neoadjuvant chemotherapy in advanced ovarian cancer: On what do we agree and disagree?
    • Vergote I, Du BA, Amant F, Heitz F, Leunen K, Harter P. Neoadjuvant chemotherapy in advanced ovarian cancer: on what do we agree and disagree? Gynecol Oncol 2013;128:6-11.
    • (2013) Gynecol Oncol , vol.128 , pp. 6-11
    • Vergote, I.1    Du, B.A.2    Amant, F.3    Heitz, F.4    Leunen, K.5    Harter, P.6
  • 47
    • 84894077956 scopus 로고    scopus 로고
    • Does neoadjuvant chemotherapy impair long-term survival for ovarian cancer patients? A nationwide Danish study
    • Fago-Olsen CL, Ottesen B, Kehlet H, Antonsen SL, Christensen IJ,Markauskas A, et al. Does neoadjuvant chemotherapy impair long-term survival for ovarian cancer patients? A nationwide Danish study. Gynecol Oncol 2014;132:292-8.
    • (2014) Gynecol Oncol , vol.132 , pp. 292-298
    • Fago-Olsen, C.L.1    Ottesen, B.2    Kehlet, H.3    Antonsen, S.L.4    Christensen, I.J.5    Markauskas, A.6
  • 48
    • 0024496836 scopus 로고
    • Neoadjuvant (cytoreductive) chemotherapy combined with intervention debulking surgery in advanced, unresected epithelial ovarian cancer
    • Lawton FG, Redman CW, Luesley DM, Chan KK, Blackledge G. Neoadjuvant (cytoreductive) chemotherapy combined with intervention debulking surgery in advanced, unresected epithelial ovarian cancer. Obstet Gynecol 1989;73:61-5.
    • (1989) Obstet Gynecol , vol.73 , pp. 61-65
    • Lawton, F.G.1    Redman, C.W.2    Luesley, D.M.3    Chan, K.K.4    Blackledge, G.5
  • 49
    • 0028231205 scopus 로고
    • Neoadjuvant chemotherapy for advanced ovarian cancer
    • Schwartz PE, Chambers JT, Makuch R. Neoadjuvant chemotherapy for advanced ovarian cancer. Gynecol Oncol 1994;53:33-7.
    • (1994) Gynecol Oncol , vol.53 , pp. 33-37
    • Schwartz, P.E.1    Chambers, J.T.2    Makuch, R.3
  • 50
    • 0033896477 scopus 로고    scopus 로고
    • Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer
    • Vergote IB, De WI, Decloedt J, Tjalma W, Van GM, van DP. Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer. Semin Oncol 2000;27:31-6.
    • (2000) Semin Oncol , vol.27 , pp. 31-36
    • Vergote, I.B.1    De, W.I.2    Decloedt, J.3    Tjalma, W.4    Van, G.M.5    Van, D.P.6
  • 51
    • 84894095209 scopus 로고    scopus 로고
    • Neoadjuvant chemotherapywith six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients unsuitable for primary surgery: Safety and effectiveness
    • da C.M. V, de Souza Fede AB, Dos Anjos CH, da Silva JR, Sanchez FB, da Silva Bessa LR, et al. Neoadjuvant chemotherapywith six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients unsuitable for primary surgery: safety and effectiveness. Gynecol Oncol 2014;132:287-91.
    • (2014) Gynecol Oncol , vol.132 , pp. 287-291
    • Da, C.M.V.1    De Souza Fede, A.B.2    Dos Anjos, C.H.3    Da Silva, J.R.4    Sanchez, F.B.5    Da Silva Bessa, L.R.6
  • 52
    • 0036498788 scopus 로고    scopus 로고
    • Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis
    • Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002;20:1248-59.
    • (2002) J Clin Oncol , vol.20 , pp. 1248-1259
    • Bristow, R.E.1    Tomacruz, R.S.2    Armstrong, D.K.3    Trimble, E.L.4    Montz, F.J.5
  • 53
    • 0028952438 scopus 로고
    • The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer
    • Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer
    • van der Burg ME, van LM, Buyse M, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1995;332:629-34.
    • (1995) N Engl J Med , vol.332 , pp. 629-634
    • Van Der Burg, M.E.1    Van, L.M.2    Buyse, M.3
  • 56
    • 77956630573 scopus 로고    scopus 로고
    • The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: Survey results from members of the Society of Gynecologic Oncologists
    • Dewdney SB, Rimel BJ, Reinhart AJ, et al. The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: survey results from members of the Society of Gynecologic Oncologists. Gynecol Oncol 2010; 119:18-21.
    • (2010) Gynecol Oncol , vol.119 , pp. 18-21
    • Dewdney, S.B.1    Rimel, B.J.2    Reinhart, A.J.3
  • 57
    • 77956640361 scopus 로고    scopus 로고
    • Neoadjuvant chemotherapy in advanced ovarian cancer: What kind of evidence is needed to convince US gynaecological oncologists?
    • Vergote I, Amant F, Leunen K. Neoadjuvant chemotherapy in advanced ovarian cancer: what kind of evidence is needed to convince US gynaecological oncologists? Gynecol Oncol 2010;119:1-2.
    • (2010) Gynecol Oncol , vol.119 , pp. 1-2
    • Vergote, I.1    Amant, F.2    Leunen, K.3
  • 58
    • 83055181259 scopus 로고    scopus 로고
    • An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT)
    • Chi DS, Musa F, Dao F, Zivanovic O, Sonoda Y, Leitao MM, et al. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). Gynecol Oncol 2012;124:10-4.
    • (2012) Gynecol Oncol , vol.124 , pp. 10-14
    • Chi, D.S.1    Musa, F.2    Dao, F.3    Zivanovic, O.4    Sonoda, Y.5    Leitao, M.M.6
  • 59
    • 83055169672 scopus 로고    scopus 로고
    • Primary surgery or neoadjuvant chemotherapy in ovarian cancer: What is the value of comparing apples with oranges?
    • Vergote I, Leunen K, Amant F. Primary surgery or neoadjuvant chemotherapy in ovarian cancer: what is the value of comparing apples with oranges? Gynecol Oncol 2012;124:1-2.
    • (2012) Gynecol Oncol , vol.124 , pp. 1-2
    • Vergote, I.1    Leunen, K.2    Amant, F.3
  • 60
    • 84920715359 scopus 로고    scopus 로고
    • Chemotherapy or upfront surgery for newly diagnosed advanced ovarian cancer: Results from the MRC CHORUS trial
    • 6-1-2013 [Ref Type: Abstract]
    • Kehoe S, Hook J, Nankivell M, et al. Chemotherapy or upfront surgery for newly diagnosed advanced ovarian cancer: results from the MRC CHORUS trial. ASCO; 6-1-2013 [Ref Type: Abstract].
    • ASCO
    • Kehoe, S.1    Hook, J.2    Nankivell, M.3
  • 61
    • 44449167562 scopus 로고    scopus 로고
    • Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer
    • Morrison J, Haldar K, Kehoe S, Lawrie TA. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane Database Syst Rev 2012;8:CD005343.
    • (2012) Cochrane Database Syst Rev , vol.8
    • Morrison, J.1    Haldar, K.2    Kehoe, S.3    Lawrie, T.A.4
  • 62
    • 0027972392 scopus 로고
    • National survey of ovarian carcinoma. IV: Patterns of care and related survival for older patients
    • Hightower RD, Nguyen HN, Averette HE, Hoskins W, Harrison T, Steren A. National survey of ovarian carcinoma. IV: patterns of care and related survival for older patients. Cancer 1994;73:377-83.
    • (1994) Cancer , vol.73 , pp. 377-383
    • Hightower, R.D.1    Nguyen, H.N.2    Averette, H.E.3    Hoskins, W.4    Harrison, T.5    Steren, A.6
  • 63
    • 23844523788 scopus 로고    scopus 로고
    • Treatment patterns by decade of life in elderly women (> or =70 years of age) with ovarian cancer
    • Uyar D, Frasure HE, Markman M, von Gruenigen VE. Treatment patterns by decade of life in elderly women (> or =70 years of age) with ovarian cancer. Gynecol Oncol 2005;98:403-8.
    • (2005) Gynecol Oncol , vol.98 , pp. 403-408
    • Uyar, D.1    Frasure, H.E.2    Markman, M.3    Von Gruenigen, V.E.4
  • 64
    • 80054725319 scopus 로고    scopus 로고
    • Morbidity, mortality and overall survival in elderly women undergoing primary surgical debulking for ovarian cancer: A delicate balance requiring individualization
    • Langstraat C, Aletti GD, Cliby WA. Morbidity, mortality and overall survival in elderly women undergoing primary surgical debulking for ovarian cancer: a delicate balance requiring individualization. Gynecol Oncol 2011;123:187-91.
    • (2011) Gynecol Oncol , vol.123 , pp. 187-191
    • Langstraat, C.1    Aletti, G.D.2    Cliby, W.A.3
  • 65
    • 84872269754 scopus 로고    scopus 로고
    • Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO Stage IIIC and IV)
    • Glasgow MA, Yu H, Rutherford TJ, Azodi M, Silasi DA, Santin AD, et al. Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO Stage IIIC and IV). J Surg Oncol 2013;107: 195-200.
    • (2013) J Surg Oncol , vol.107 , pp. 195-200
    • Glasgow, M.A.1    Yu, H.2    Rutherford, T.J.3    Azodi, M.4    Silasi, D.A.5    Santin, A.D.6
  • 66
    • 84875447641 scopus 로고    scopus 로고
    • Does neoadjuvant chemotherapy decrease the risk of hospital readmission following debulking surgery?
    • Worley Jr MJ, Guseh SH, Rauh-Hain JA, Williams KA, Muto MG, Feltmate CM, et al. Does neoadjuvant chemotherapy decrease the risk of hospital readmission following debulking surgery? Gynecol Oncol 2013;129:69-73.
    • (2013) Gynecol Oncol , vol.129 , pp. 69-73
    • Worley, M.J.1    Guseh, S.H.2    Rauh-Hain, J.A.3    Williams, K.A.4    Muto, M.G.5    Feltmate, C.M.6
  • 67
    • 80052157624 scopus 로고    scopus 로고
    • Thirty-day mortality after primary cytoreductive surgery for advanced ovarian cancer in the elderly
    • Thrall MM, Goff BA, Symons RG, Flum DR, Gray HJ. Thirty-day mortality after primary cytoreductive surgery for advanced ovarian cancer in the elderly. Obstet Gynecol 2011;118:537-47.
    • (2011) Obstet Gynecol , vol.118 , pp. 537-547
    • Thrall, M.M.1    Goff, B.A.2    Symons, R.G.3    Flum, D.R.4    Gray, H.J.5
  • 68
    • 84898041460 scopus 로고    scopus 로고
    • Comparative effectiveness of upfront treatment strategies in elderly women with ovarian cancer
    • Wright JD, Ananth CV, Tsui J, Glied SA, Burke WM, Lu YS, et al. Comparative effectiveness of upfront treatment strategies in elderly women with ovarian cancer. Cancer 2014;120:1246-54.
    • (2014) Cancer , vol.120 , pp. 1246-1254
    • Wright, J.D.1    Ananth, C.V.2    Tsui, J.3    Glied, S.A.4    Burke, W.M.5    Lu, Y.S.6
  • 71
    • 80052738105 scopus 로고    scopus 로고
    • Impact of obesity on operative morbidity and clinical outcome in primary epithelial ovarian cancer after optimal primary tumor debulking
    • Fotopoulou C, Richter R, Braicu EI, Kuhberg M, Feldheiser A, Schefold JC, et al. Impact of obesity on operative morbidity and clinical outcome in primary epithelial ovarian cancer after optimal primary tumor debulking. Ann Surg Oncol 2011;18: 2629-37.
    • (2011) Ann Surg Oncol , vol.18 , pp. 2629-2637
    • Fotopoulou, C.1    Richter, R.2    Braicu, E.I.3    Kuhberg, M.4    Feldheiser, A.5    Schefold, J.C.6
  • 73
    • 84866452518 scopus 로고    scopus 로고
    • Obesity and ovarian cancer survival: A systematic review and meta-analysis
    • Protani MM, Nagle CM, Webb PM. Obesity and ovarian cancer survival: a systematic review and meta-analysis. Cancer Prev Res (Phila) 2012;5:901-10.
    • (2012) Cancer Prev Res (Phila) , vol.5 , pp. 901-910
    • Protani, M.M.1    Nagle, C.M.2    Webb, P.M.3
  • 78
    • 44549088304 scopus 로고    scopus 로고
    • Carboplatin dosing in obese women with ovarian cancer: A Gynecologic Oncology Group study
    • Wright JD, Tian C,Mutch DG, Herzog TJ, Nagao S, Fujiwara K, et al. Carboplatin dosing in obese women with ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2008;109:353-8.
    • (2008) Gynecol Oncol , vol.109 , pp. 353-358
    • Wright, J.D.1    Tian, C.2    Mutch, D.G.3    Herzog, T.J.4    Nagao, S.5    Fujiwara, K.6
  • 79
    • 84897082114 scopus 로고    scopus 로고
    • Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS)
    • Au-Yeung G, Webb PM, DeFazio A, Fereday S, Bressel M, Mileshkin L. Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS). Gynecol Oncol 2014;133: 16-22.
    • (2014) Gynecol Oncol , vol.133 , pp. 16-22
    • Au-Yeung, G.1    Webb, P.M.2    DeFazio, A.3    Fereday, S.4    Bressel, M.5    Mileshkin, L.6
  • 80
    • 43049127201 scopus 로고    scopus 로고
    • Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial
    • Barrett SV, Paul J, Hay A, Vasey PA, Kaye SB, Glasspool RM. Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial. Ann Oncol 2008;19:898-902.
    • (2008) Ann Oncol , vol.19 , pp. 898-902
    • Barrett, S.V.1    Paul, J.2    Hay, A.3    Vasey, P.A.4    Kaye, S.B.5    Glasspool, R.M.6
  • 82
    • 33947316123 scopus 로고    scopus 로고
    • Analysis of factors impacting operability in stage IV ovarian cancer: Rationale use of a triage system
    • Aletti GD, Dowdy SC, Podratz KC, Cliby WA. Analysis of factors impacting operability in stage IV ovarian cancer: rationale use of a triage system. Gynecol Oncol 2007; 105:84-9.
    • (2007) Gynecol Oncol , vol.105 , pp. 84-89
    • Aletti, G.D.1    Dowdy, S.C.2    Podratz, K.C.3    Cliby, W.A.4
  • 84
    • 80053633748 scopus 로고    scopus 로고
    • Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer
    • Rauh-Hain JA, Growdon WB, Rodriguez N, et al. Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer. Gynecol Oncol 2011;120: S12-3.
    • (2011) Gynecol Oncol , vol.120 , pp. S12-S13
    • Rauh-Hain, J.A.1    Growdon, W.B.2    Rodriguez, N.3
  • 85
    • 84865496961 scopus 로고    scopus 로고
    • Neoadjuvant chemotherapy, interval debulking surgery or primary surgery in ovarian carcinoma FIGO stage IV?
    • Trope CG, Elstrand MB, Sandstad B, Davidson B, Oksefjell H. Neoadjuvant chemotherapy, interval debulking surgery or primary surgery in ovarian carcinoma FIGO stage IV? Eur J Cancer 2012;48:2146-54.
    • (2012) Eur J Cancer , vol.48 , pp. 2146-2154
    • Trope, C.G.1    Elstrand, M.B.2    Sandstad, B.3    Davidson, B.4    Oksefjell, H.5
  • 86
    • 37849025830 scopus 로고    scopus 로고
    • Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: A Gynecologic Oncology Group study
    • Winter III WE, Maxwell GL, Tian C, et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2008;26:83-9.
    • (2008) J Clin Oncol , vol.26 , pp. 83-89
    • Winter, W.E.1    Maxwell, G.L.2    Tian, C.3
  • 87
    • 84884902788 scopus 로고    scopus 로고
    • Which patients benefitmost fromprimary surgery or neoadjuvant chemotherapy in stage IIIC or IV ovarian cancer? An exploratory analysis of the European Organisation for Research and Treatment of Cancer 55971 randomised trial
    • van Meurs HS, Tajik P, Hof MH, Vergote I, Kenter GG, Mol BW, et al. Which patients benefitmost fromprimary surgery or neoadjuvant chemotherapy in stage IIIC or IV ovarian cancer? An exploratory analysis of the European Organisation for Research and Treatment of Cancer 55971 randomised trial. Eur J Cancer 2013;49:3191-201.
    • (2013) Eur J Cancer , vol.49 , pp. 3191-3201
    • Van Meurs, H.S.1    Tajik, P.2    Hof, M.H.3    Vergote, I.4    Kenter, G.G.5    Mol, B.W.6
  • 88
    • 33947322200 scopus 로고    scopus 로고
    • Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease
    • Hou JY, Kelly MG, Yu H, et al. Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease. Gynecol Oncol 2007;105:211-7.
    • (2007) Gynecol Oncol , vol.105 , pp. 211-217
    • Hou, J.Y.1    Kelly, M.G.2    Yu, H.3
  • 89
    • 34447326204 scopus 로고    scopus 로고
    • Treatment of FIGO stage IV ovarian carcinoma: Results of primary surgery or interval surgery after neoadjuvant chemotherapy: A retrospective study
    • Rafii A, Deval B, Geay JF, Chopin N, Paoletti X, Paraiso D, et al. Treatment of FIGO stage IV ovarian carcinoma: results of primary surgery or interval surgery after neoadjuvant chemotherapy: a retrospective study. Int J Gynecol Cancer 2007;17: 777-83.
    • (2007) Int J Gynecol Cancer , vol.17 , pp. 777-783
    • Rafii, A.1    Deval, B.2    Geay, J.F.3    Chopin, N.4    Paoletti, X.5    Paraiso, D.6
  • 90
    • 84891161285 scopus 로고    scopus 로고
    • Staging classification for cancer of the ovary, fallopian tube, and peritoneum
    • Prat J. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet 2014;124:1-5.
    • (2014) Int J Gynaecol Obstet , vol.124 , pp. 1-5
    • Prat, J.1
  • 91
    • 0034307229 scopus 로고    scopus 로고
    • A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography
    • Bristow RE, Duska LR, Lambrou NC, Fishman EK, O'Neill MJ, Trimble EL, et al. A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography. Cancer 2000;89:1532-40.
    • (2000) Cancer , vol.89 , pp. 1532-1540
    • Bristow, R.E.1    Duska, L.R.2    Lambrou, N.C.3    Fishman, E.K.4    O'Neill, M.J.5    Trimble, E.L.6
  • 92
    • 3042823262 scopus 로고    scopus 로고
    • The utility of computed tomography scans in predicting suboptimal cytoreductive surgery in women with advanced ovarian carcinoma
    • Dowdy SC, Mullany SA, Brandt KR, Huppert BJ, Cliby WA. The utility of computed tomography scans in predicting suboptimal cytoreductive surgery in women with advanced ovarian carcinoma. Cancer 2004;101:346-52.
    • (2004) Cancer , vol.101 , pp. 346-352
    • Dowdy, S.C.1    Mullany, S.A.2    Brandt, K.R.3    Huppert, B.J.4    Cliby, W.A.5
  • 93
    • 33846995117 scopus 로고    scopus 로고
    • Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer
    • Axtell AE, Lee MH, Bristow RE, Dowdy SC, Cliby WA, Raman S, et al. Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer. J Clin Oncol 2007;25:384-9.
    • (2007) J Clin Oncol , vol.25 , pp. 384-389
    • Axtell, A.E.1    Lee, M.H.2    Bristow, R.E.3    Dowdy, S.C.4    Cliby, W.A.5    Raman, S.6
  • 94
    • 84908322353 scopus 로고    scopus 로고
    • A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer
    • Suidan RS, Ramirez PT, Sarasohn DM, Teitcher JB, Mironov S, Iyer RB, et al. A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer. Gynecol Oncol 2014;134:455-61.
    • (2014) Gynecol Oncol , vol.134 , pp. 455-461
    • Suidan, R.S.1    Ramirez, P.T.2    Sarasohn, D.M.3    Teitcher, J.B.4    Mironov, S.5    Iyer, R.B.6
  • 95
    • 52449111259 scopus 로고    scopus 로고
    • Diagnostic accuracy of integrated FDG-PET/contrast-enhanced CT in staging ovarian cancer: Comparison with enhanced CT
    • Kitajima K, Murakami K, Yamasaki E, Kaji Y, Fukasawa I, Inaba N, et al. Diagnostic accuracy of integrated FDG-PET/contrast-enhanced CT in staging ovarian cancer: comparison with enhanced CT. Eur J Nucl Med Mol Imaging 2008;35:1912-20.
    • (2008) Eur J Nucl Med Mol Imaging , vol.35 , pp. 1912-1920
    • Kitajima, K.1    Murakami, K.2    Yamasaki, E.3    Kaji, Y.4    Fukasawa, I.5    Inaba, N.6
  • 96
    • 64249100608 scopus 로고    scopus 로고
    • (18) F-FDG-PET/CT to select patients with peritoneal carcinomatosis for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
    • Pfannenberg C, Konigsrainer I, Aschoff P, Oksuz MO, Zieker D, Beckert S, et al. (18) F-FDG-PET/CT to select patients with peritoneal carcinomatosis for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2009; 16:1295-303.
    • (2009) Ann Surg Oncol , vol.16 , pp. 1295-1303
    • Pfannenberg, C.1    Konigsrainer, I.2    Aschoff, P.3    Oksuz, M.O.4    Zieker, D.5    Beckert, S.6
  • 97
    • 0346881480 scopus 로고    scopus 로고
    • Incremental benefits of FDG positron emission tomography over CT alone for the preoperative staging of ovarian cancer
    • Yoshida Y, Kurokawa T, Kawahara K, Tsuchida T, Okazawa H, Fujibayashi Y, et al. Incremental benefits of FDG positron emission tomography over CT alone for the preoperative staging of ovarian cancer. AJR Am J Roentgenol 2004;182:227-33.
    • (2004) AJR Am J Roentgenol , vol.182 , pp. 227-233
    • Yoshida, Y.1    Kurokawa, T.2    Kawahara, K.3    Tsuchida, T.4    Okazawa, H.5    Fujibayashi, Y.6
  • 98
    • 84886089147 scopus 로고    scopus 로고
    • A prospective comparison of integrated FDG-PET/contrast-enhanced CT and contrastenhanced CT for pretreatment imaging of advanced epithelial ovarian cancer
    • Hynninen J, Kemppainen J, Lavonius M, Virtanen J,Matomaki J, Oksa S, et al. A prospective comparison of integrated FDG-PET/contrast-enhanced CT and contrastenhanced CT for pretreatment imaging of advanced epithelial ovarian cancer. Gynecol Oncol 2013;131:389-94.
    • (2013) Gynecol Oncol , vol.131 , pp. 389-394
    • Hynninen, J.1    Kemppainen, J.2    Lavonius, M.3    Virtanen, J.4    Matomaki, J.5    Oksa, S.6
  • 102
    • 13844281566 scopus 로고    scopus 로고
    • Role of laparoscopy to assess the chance of optimal cytoreductive surgery in advanced ovarian cancer: A pilot study
    • Fagotti A, Fanfani F, Ludovisi M, Lo VR, Bifulco G, Testa AC, et al. Role of laparoscopy to assess the chance of optimal cytoreductive surgery in advanced ovarian cancer: a pilot study. Gynecol Oncol 2005;96:729-35.
    • (2005) Gynecol Oncol , vol.96 , pp. 729-735
    • Fagotti, A.1    Fanfani, F.2    Ludovisi, M.3    Lo, V.R.4    Bifulco, G.5    Testa, A.C.6
  • 103
    • 50149114455 scopus 로고    scopus 로고
    • External validation of a laparoscopic-based score to evaluate resectability of advanced ovarian cancers: Clues for a simplified score
    • Brun JL, Rouzier R, Uzan S, Darai E. External validation of a laparoscopic-based score to evaluate resectability of advanced ovarian cancers: clues for a simplified score. Gynecol Oncol 2008;110:354-9.
    • (2008) Gynecol Oncol , vol.110 , pp. 354-359
    • Brun, J.L.1    Rouzier, R.2    Uzan, S.3    Darai, E.4
  • 104
    • 33748348989 scopus 로고    scopus 로고
    • A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: A pilot study
    • Fagotti A, Ferrandina G, Fanfani F, Ercoli A, Lorusso D, Rossi M, et al. A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study. Ann Surg Oncol 2006;13:1156-61.
    • (2006) Ann Surg Oncol , vol.13 , pp. 1156-1161
    • Fagotti, A.1    Ferrandina, G.2    Fanfani, F.3    Ercoli, A.4    Lorusso, D.5    Rossi, M.6
  • 105
    • 57149125155 scopus 로고    scopus 로고
    • Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma
    • Fagotti A, Ferrandina G, Fanfani F, Garganese G, Vizzielli G, Carone V, et al. Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma. Am J Obstet Gynecol 2008;199:642-6.
    • (2008) Am J Obstet Gynecol , vol.199 , pp. 642-646
    • Fagotti, A.1    Ferrandina, G.2    Fanfani, F.3    Garganese, G.4    Vizzielli, G.5    Carone, V.6
  • 106
    • 84886095043 scopus 로고    scopus 로고
    • Introduction of staging laparoscopy in the management of advanced epithelial ovarian, tubal and peritoneal cancer: Impact on prognosis in a single institution experience
    • Fagotti A, Vizzielli G, Fanfani F, Costantini B, Ferrandina G, Gallotta V, et al. Introduction of staging laparoscopy in the management of advanced epithelial ovarian, tubal and peritoneal cancer: impact on prognosis in a single institution experience. Gynecol Oncol 2013;131:341-6.
    • (2013) Gynecol Oncol , vol.131 , pp. 341-346
    • Fagotti, A.1    Vizzielli, G.2    Fanfani, F.3    Costantini, B.4    Ferrandina, G.5    Gallotta, V.6
  • 107
    • 84918770603 scopus 로고    scopus 로고
    • Influence of intraperitoneal dissemination assessed by laparoscopy on prognosis of advanced ovarian cancer: An exploratory analysis of a single-institution experience
    • Vizzielli G, Costantini B, Tortorella L, Petrillo M, Fanfani F, Chiantera V, et al. Influence of intraperitoneal dissemination assessed by laparoscopy on prognosis of advanced ovarian cancer: an exploratory analysis of a single-institution experience. Ann Surg Oncol 2014;21:3170-7.
    • (2014) Ann Surg Oncol , vol.21 , pp. 3170-3177
    • Vizzielli, G.1    Costantini, B.2    Tortorella, L.3    Petrillo, M.4    Fanfani, F.5    Chiantera, V.6
  • 108
    • 84886798436 scopus 로고    scopus 로고
    • A multicentric trial (Olympia-MITO 13) on the accuracy of laparoscopy to assess peritoneal spread in ovarian cancer
    • Fagotti A, Vizzielli G, De IP, Surico D, Buda A,Mandato VD, et al. A multicentric trial (Olympia-MITO 13) on the accuracy of laparoscopy to assess peritoneal spread in ovarian cancer. Am J Obstet Gynecol 2013;209:462.
    • (2013) Am J Obstet Gynecol , vol.209 , pp. 462
    • Fagotti, A.1    Vizzielli, G.2    De Surico D, I.P.3    Buda, A.4    Mandato, V.D.5
  • 109
    • 84856017023 scopus 로고    scopus 로고
    • Laparoscopy to predict the result of primary cytoreductive surgery in advanced ovarian cancer patients (LapOvCa-trial): A multicentre randomized controlled study
    • Rutten MJ, Gaarenstroom KN, Van GT, van Meurs HS, Arts HJ, Bossuyt PM, et al. Laparoscopy to predict the result of primary cytoreductive surgery in advanced ovarian cancer patients (LapOvCa-trial): a multicentre randomized controlled study. BMC Cancer 2012;12:31.
    • (2012) BMC Cancer , vol.12 , pp. 31
    • Rutten, M.J.1    Gaarenstroom, K.N.2    Van, G.T.3    Van Meurs, H.S.4    Arts, H.J.5    Bossuyt, P.M.6
  • 112
    • 29144450706 scopus 로고    scopus 로고
    • Ovarian cancer surgical resectability: Relative impact of disease, patient status, and surgeon
    • Aletti GD, Gostout BS, Podratz KC, Cliby WA. Ovarian cancer surgical resectability: relative impact of disease, patient status, and surgeon. Gynecol Oncol 2006;100: 33-7.
    • (2006) Gynecol Oncol , vol.100 , pp. 33-37
    • Aletti, G.D.1    Gostout, B.S.2    Podratz, K.C.3    Cliby, W.A.4
  • 113
    • 80052693068 scopus 로고    scopus 로고
    • Prognostic significance of splenectomy as part of initial cytoreductive surgery in ovarian cancer
    • McCann CK, Growdon WB, Munro EG, et al. Prognostic significance of splenectomy as part of initial cytoreductive surgery in ovarian cancer. Ann Surg Oncol 2011;18: 2912-8.
    • (2011) Ann Surg Oncol , vol.18 , pp. 2912-2918
    • McCann, C.K.1    Growdon, W.B.2    Munro, E.G.3
  • 114
    • 34250205243 scopus 로고    scopus 로고
    • Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR)
    • Wimberger P, Lehmann N, Kimmig R, et al. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecol Oncol 2007;106:69-74.
    • (2007) Gynecol Oncol , vol.106 , pp. 69-74
    • Wimberger, P.1    Lehmann, N.2    Kimmig, R.3
  • 115
    • 79955665860 scopus 로고    scopus 로고
    • Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer
    • Ang C, Chan KK, Bryant A, Naik R, Dickinson HO. Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer. Cochrane Database Syst Rev 2011:CD007697.
    • (2011) Cochrane Database Syst Rev
    • Ang, C.1    Chan, K.K.2    Bryant, A.3    Naik, R.4    Dickinson, H.O.5
  • 117
    • 84903188204 scopus 로고    scopus 로고
    • Spatial analysis of adherence to treatment guidelines for advanced-stage ovarian cancer and the impact of race and socioeconomic status
    • Bristow RE, Chang J, Ziogas A, Anton-Culver H, Vieira VM. Spatial analysis of adherence to treatment guidelines for advanced-stage ovarian cancer and the impact of race and socioeconomic status. Gynecol Oncol 2014;134:60-7.
    • (2014) Gynecol Oncol , vol.134 , pp. 60-67
    • Bristow, R.E.1    Chang, J.2    Ziogas, A.3    Anton-Culver, H.4    Vieira, V.M.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.